Kundan Mishra1, Suman Pramanik1, Rajeev Sandal2, Aditya Jandial3, Kamal Kant Sahu4, Kanwaljeet Singh5, Sanjeev Khera6, Ashok Meshram7, Harshit Khurana8, Venkatesan Somasundaram5, Rajiv Kumar1,9, Rajan Kapoor1,10, Tarun Verma1, Sanjeevan Sharma1,11, Jasjit Singh1,12, Satyaranjan Das1,8, Tathagat Chaterjee5, Ajay Sharma1,12, Velu Nair1,13. 1. Department of Clinical Hematology and Stem Cell Transplant, Army Hospital (Research & Referral) Delhi, India. 2. Department of Radiotherapy and Oncology, IGMC Shimla Himachal Pradesh, India. 3. Department of Internal Medicine, PGIMER Chandigarh, India. 4. Division of Hematology and Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah Salt Lake City, Zip 84112, Utah, US. 5. Department of Lab Sciences and Molecular Medicine, Army Hospital (Research & Referral) Delhi, India. 6. Department of Pediatrics, Army Hospital (Research & Referral) Delhi, India. 7. Department of Internal Medicine, INHS Asvini Mumbai, India. 8. Department of Internal Medicine, Command Hospital (Southern Command) Pune, India. 9. Department of Internal Medicine, Command Hospital (Air Force) Bangaluru, India. 10. Department of Internal Medicine, Command Hospital (Eastern Command) Kolkata, India. 11. Department of Internal Medicine, Command Hospital (Central Command) Lucknow, India. 12. Department of Clinical Hematology and Stem Cell Transplant, Sir Ganga Ram Hospital Delhi, India. 13. Group Head-Medical Services and Chief Consultant-Haemato-Oncology & Bone Marrow Transplant, Apollo Comprehensive Blood & Cancer Center (CBCC) Cancer Care Ahmedabad, India.
Abstract
BACKGROUND: Immune thrombocytopenia (ITP) is a benign hematological disorder characterized by low platelet counts in peripheral blood and spectrum of various bleeding manifestations. Azathioprine is one of the effective, readily available, and affordable immunosupressants available for ITP management in developing countries. We aimed to study the efficacy and long-term safety profile of our patients with ITP who were treated with azathioprine. METHOD: This was a retrospective, single-center study conducted at a tertiary care hospital in Northern India. The patients who had received at least one line of therapy before receiving azathioprine were included in this study. All patients received oral azathioprine at a dose of 1 mg/kg/day (50 mg or 100 mg tablet formulations were used), which was increased up to 2 mg/kg/day depending upon the response and adverse effects. RESULT: Sixty-three patients were analyzed. Their median age was 28 years (range 15-68); 29/63 patients (46.03%) were females. The median duration from diagnosis to azathioprine initiation was 539 days (323 days-980.5 days). The patients included in the study had received a median of 3 (range 1-6) prior lines of therapies; 38/63 patients (60.32%) had received ≥3 prior therapies. Six patients (9.5%) had relapsed after splenectomy, and 16 patients (25.4%) had relapsed after receiving rituximab. The mean baseline platelet count was 10000/μL. The median time to response was 95 days (90 days-not reached) and the cumulative overall response rate (complete and partial response) at day 90 was 38.1%. Only one patient achieved complete response with azathioprine in our study. The cumulative rate of relapse at five years was 21.2%. Twenty-six patients stopped azathioprine after achieving some response (CR/PR) with Azathioprine for a median duration of 1067.5 days (range: 236 days-2465 days). They were followed up for a median of 870 days (range: 392 days-1928 days), and twelve of them relapsed. Twenty-six patients (26/63, 41.27%) reported one or more adverse events while on azathioprine. Leucopenia was the most frequent adverse event, followed by anemia and hepatobiliary laboratory abnormalities. Serious adverse events (grade ≥3 CTCAEv4) were noted in three patients (4.7%). One patient succumbed to severe sepsis multiorgan dysfunction while being on treatment. CONCLUSION: We conclude that azathioprine has a good response rate in chronic ITP patients. It is well-tolerated with minimal and manageable side effects. AJBR
BACKGROUND: Immune thrombocytopenia (ITP) is a benign hematological disorder characterized by low platelet counts in peripheral blood and spectrum of various bleeding manifestations. Azathioprine is one of the effective, readily available, and affordable immunosupressants available for ITP management in developing countries. We aimed to study the efficacy and long-term safety profile of our patients with ITP who were treated with azathioprine. METHOD: This was a retrospective, single-center study conducted at a tertiary care hospital in Northern India. The patients who had received at least one line of therapy before receiving azathioprine were included in this study. All patients received oral azathioprine at a dose of 1 mg/kg/day (50 mg or 100 mg tablet formulations were used), which was increased up to 2 mg/kg/day depending upon the response and adverse effects. RESULT: Sixty-three patients were analyzed. Their median age was 28 years (range 15-68); 29/63 patients (46.03%) were females. The median duration from diagnosis to azathioprine initiation was 539 days (323 days-980.5 days). The patients included in the study had received a median of 3 (range 1-6) prior lines of therapies; 38/63 patients (60.32%) had received ≥3 prior therapies. Six patients (9.5%) had relapsed after splenectomy, and 16 patients (25.4%) had relapsed after receiving rituximab. The mean baseline platelet count was 10000/μL. The median time to response was 95 days (90 days-not reached) and the cumulative overall response rate (complete and partial response) at day 90 was 38.1%. Only one patient achieved complete response with azathioprine in our study. The cumulative rate of relapse at five years was 21.2%. Twenty-six patients stopped azathioprine after achieving some response (CR/PR) with Azathioprine for a median duration of 1067.5 days (range: 236 days-2465 days). They were followed up for a median of 870 days (range: 392 days-1928 days), and twelve of them relapsed. Twenty-six patients (26/63, 41.27%) reported one or more adverse events while on azathioprine. Leucopenia was the most frequent adverse event, followed by anemia and hepatobiliary laboratory abnormalities. Serious adverse events (grade ≥3 CTCAEv4) were noted in three patients (4.7%). One patient succumbed to severe sepsis multiorgan dysfunction while being on treatment. CONCLUSION: We conclude that azathioprine has a good response rate in chronic ITP patients. It is well-tolerated with minimal and manageable side effects. AJBR
Authors: Thomas M Atkinson; Sean J Ryan; Antonia V Bennett; Angela M Stover; Rebecca M Saracino; Lauren J Rogak; Sarah T Jewell; Konstantina Matsoukas; Yuelin Li; Ethan Basch Journal: Support Care Cancer Date: 2016-06-03 Impact factor: 3.603
Authors: B S Poudyal; B Sapkota; G S Shrestha; S Thapalia; B Gyawali; S Tuladhar Journal: JNMA J Nepal Med Assoc Date: 2016 Jul-Sep Impact factor: 0.406
Authors: Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely Journal: Blood Adv Date: 2019-12-10
Authors: K Subramaniam; D Yeung; F Grimpen; J Joseph; K Fay; M Buckland; D Talaulikar; J Elijah; A C Clarke; P Pavli; J Moore Journal: Intern Med J Date: 2014-03 Impact factor: 2.048